<DOC>
	<DOCNO>NCT01888978</DOCNO>
	<brief_summary>This study patient metastatic pancreatic cancer ( cancer spread part body ) . The purpose study determine whether molecularly tailor therapy improve effectiveness standard chemotherapy combination patient metastatic pancreatic cancer . A series special test perform sample tumor , base result subject assign one seven chemotherapy treatment , combination two standard chemotherapy . Each combination safely use patient pancreatic type cancer . The purpose study determine ability personalize therapy manner , determine many patient large study would need . A second purpose determine one doublet well another . Rather , second purpose show patient enrol protocol assign doublet base tumor 's molecular analysis ( molecular tailoring ) , treatment response well would expect compare patient treat past molecular tailoring .</brief_summary>
	<brief_title>Molecularly Tailored Therapy Pancreas Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically prove pancreatic adenocarcinoma measurable disease Biopsy accessible tumor deposit ECOG performance status 02 Age &gt; /= 18 year Subjects brain metastasis history previously treat brain metastasis Adequate hepatic , renal , bone marrow function Partial thromboplastin time must &lt; /= 1.5 x upper normal limit institution 's normal range INR &lt; 1.5 Life expectancy &gt; 12 week Women childbearing potential must negative seum pregnancy test within 14 day prior initiation treatment Subject capable understanding comply parameter outline protocol able sign date consent CNS metastases meet criterion outline inclusion criterion Active severe infection know chronic infection HIV hepatitis B virus Cardiovascular disease Life threaten visceral disease severe concurrent disease Women pregnant , breastfeeding , woman childbearing potential use dual form effective contraception Anticipated patient survival 3 month Patients receive investigational agent History allergic reaction attribute compound similar chemical biological composition gemcitabine , oxaliplatin , 5FU , docetaxel irinotecan Uncontrolled intercurrent illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Pancreas</keyword>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>chemotherapy</keyword>
</DOC>